Supernus Pharmaceuticals Initiates Phase III Clinical Trial for SPN-804 in Refractory Partial Onset Epileptic Seizures
SPN-804 is a novel controlled release once-per-day dosage form of oxcarbazepine that is designed to improve compliance and reduce adverse events. Earlier this year, Supernus completed a proof-of-concept study where SPN-804 showed significant improvement in key adverse events compared to the reference product Trileptal®.
"Initiating our Phase III trial for SPN-804 is a major milestone for Supernus and an important step toward addressing a significant unmet need in the treatment of epilepsy," said Jack Khattar, president and CEO. "We are excited about SPN-804 and its potential for offering epilepsy patients an effective anti-convulsant therapy with much-needed lower side effects and the convenience of once-per-day dosing. Reaching this clinical development milestone for SPN-804 demonstrates the significant progress Supernus has made in the three years since we started building our pipeline."
Supernus Pharmaceuticals, Inc. is focused on developing specialty CNS products that are designed to improve patient compliance, reduce side effects, and address unmet medical needs. The company's extensive expertise in product development is well proven over the past 18 years. Supernus started its operations in December 2005 when it purchased significantly all the assets of Shire Laboratories, Inc. including technologies, intellectual property, and product partnerships. Products using the technologies and expertise of Supernus, and when formerly Shire Laboratories, include: Adderall XR®, Carbatrol® and Equetro® that are marketed by Shire or its sub-licensees, Oracea® that is marketed by Galderma, and Sanctura® XR that is marketed by Allergan in the U.S.
CONTACT:
Russell "Rip" Wilson
Chief Financial Officer
Supernus Pharmaceuticals, Inc.
Tel: 301 838-2522